Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma - Trial NCT06240143
Access comprehensive clinical trial information for NCT06240143 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by The Netherlands Cancer Institute and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The Netherlands Cancer Institute
Timeline & Enrollment
Phase 1/2
Feb 01, 2024
May 01, 2026
Primary Outcome
Feasibility,Effectivity
Summary
This open label, single country trial will test if local injection of low-dose ipilimumab and
 nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma
 patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06240143
Non-Device Trial